ENSC

Announcements

Nothing here yet

Daily updates

• Ensysce completes Cy Biopharma acquisition and adds orphan-designated CRPS therapyAug 6, 2026
• USPTO allows patent application for abuse-resistant amphetamine prodrug technologyAug 4, 2026

FDA designations

Nothing here yet

News

• Ensysce Biosciences submits the Phase 2 protocol for CY200, a neuroplastigen for treating complex regional pain syndrome, to the UK MHRASep 24, 2026
• Ensysce Biosciences completed the final phase of the PF614-MPAR-102 clinical studyAug 31, 2026
• Ensysce Biosciences expands patent protection for MPAR overdose protection technologyMay 12, 2026
• Ensysce Biosciences secured IRB approval for the final phase of its PF614 clinical studyApr 17, 2026
• Ensysce Biosciences updated enrollment progress in Phase 3 PF614 opioid trialJan 28, 2026